Related Experiment Video
Updated: Apr 11, 2026
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
34.4K
Safe anticoagulation when heart and lungs are "on vacation"
Marina A Dobrovolskaia1, Scott E McNeil1
1Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA.
Annals of Translational Medicine
|June 6, 2015
Summary
A new antibody inhibiting Factor XIIa offers a safe and effective alternative to heparin for preventing blood clots during heart-lung machine procedures like CPB and ECMO, reducing bleeding risks.
Area of Science:
- Cardiovascular Surgery
- Hematology
- Biotechnology
Background:
- Coronary pulmonary bypass (CPB) and extracorporeal membrane oxygenation (ECMO) require external blood circulation, posing risks of dangerous blood coagulation.
- Current anticoagulant heparin, while effective, often leads to life-threatening bleeding complications.
- There is a critical need for safer anticoagulation strategies in CPB and ECMO procedures.
Purpose of the Study:
- To evaluate a novel fully human antibody (3F7) targeting Factor XIIa as a potential heparin alternative.
- To assess the efficacy and safety of this antibody in preventing thrombosis during extracorporeal circulation.
Main Methods:
- Investigated a recombinant fully human antibody (3F7) that inhibits Factor XIIa.
- Examined the potential of this antibody as an anticoagulant in the context of CPB and ECMO procedures.
Main Results:
- The 3F7 antibody demonstrated both efficacy in preventing blood coagulation and safety, unlike heparin.
- This novel antibody presents a promising alternative to traditional anticoagulants.
Conclusions:
- The Factor XIIa inhibiting antibody (3F7) represents a significant advancement in anticoagulation for CPB and ECMO.
- Further clinical translation of this antibody could improve patient outcomes by mitigating bleeding risks associated with current therapies.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
01:29Venous Thrombosis III: Interprofessional Care
471
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
471
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
680
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
680
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
1.4K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.4K
01:28Acute Coronary Syndrome IV: Interprofessional Care
487
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
487